10-K: DarioHealth Reports Mixed 2025 Results Amid Strategic Review

DarioHealth Corp. reported a decrease in 2025 revenues and continued net losses, alongside significant operational efficiency gains and customer growth, while initiating a strategic review to maximize shareholder value.

Summary

• Revenues for the year ended December 31, 2025, decreased by 17.3% to $22.359 million from $27.040 million in 2024, primarily due to the non-renewal of one customer acquired through the Twill acquisition.
• Net loss for 2025 was $41.714 million, a slight improvement from $42.747 million in 2024, driven by significant reductions in operating expenses.
• Net loss attributable to common shareholders worsened to $61.735 million in 2025 from $40.982 million in 2024, largely due to changes in finance income/expenses related to warrant revaluation and preferred stock conversions.
• Operating expenses saw substantial reductions: Research and Development decreased by 43% to $13.791 million, Sales and Marketing decreased by 22.8% to $20.338 million, and General and Administrative decreased by 25.8% to $15.191 million.
• Cash used in operating activities improved to $25.941 million in 2025 from $38.562 million in 2024.
• The company successfully raised approximately $24.128 million in net proceeds from equity offerings in January and September 2025.
• DarioHealth refinanced its existing credit facility with a new $32.5 million Callodine Loan Facility in April 2025, with principal repayments deferred until May 2028.
• The company did not meet a financial covenant under the Callodine Credit Agreement on August 15, 2025, but utilized an Equity Cure and subsequently amended the agreement in November 2025 to reset covenants and modify liquidity requirements.
• Employer customer base grew significantly to 167 in 2025, up from 53 in 2024, adding 85 new accounts and surpassing an internal goal of 40.
• A comprehensive strategic review was initiated on September 25, 2025, to explore options including a sale, merger, or strategic business combination.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period with declining revenue and worsening net loss for common shareholders, despite positive operational efficiency and customer growth. The ongoing need for capital raises and a missed debt covenant indicate continued financial pressure, though the strategic review offers potential for future value.

Positives

• Significant reduction in operating expenses, including a 43% decrease in R&D and a 22.8% decrease in sales and marketing, demonstrating improved operational efficiency.
• Improved cash flow from operating activities, reducing cash burn from $38.562 million in 2024 to $25.941 million in 2025.
• Strong customer growth in the B2B employer segment, increasing from 53 customers in 2024 to 167 in 2025, exceeding internal targets.
• Successful refinancing of debt with a new $32.5 million Callodine Loan Facility, deferring principal repayments until May 2028, providing additional operational flexibility.
• Continued investment and innovation in AI technologies (DarioIQ, DarioSHIFT) and strategic collaborations (OneStep) to enhance platform capabilities and market reach.
• Extensive clinical evidence base with over 100 studies demonstrating positive health outcomes and significant medical cost savings for users across multiple conditions.

Negatives

• Overall revenues decreased by 17.3% to $22.359 million in 2025, primarily due to the non-renewal of a key customer acquired through the Twill acquisition.
• Net loss attributable to common shareholders worsened by 50.6% to $61.735 million in 2025, largely influenced by financial expenses related to warrant revaluation and preferred stock conversions.
• The company continues to incur significant losses and negative cash flows from operations, with an accumulated deficit of $452.078 million as of December 31, 2025.
• A financial covenant under the Callodine Credit Agreement was not met on August 15, 2025, requiring an Equity Cure and subsequent amendment, indicating ongoing financial challenges.
• The company remains dependent on raising additional funds to support operations and achieve profitability, with no assurance of obtaining sufficient capital on acceptable terms.

Risks

• Lack of positive cash flow and future capital needs, potentially leading to dilution for existing stockholders or hindering operations.
• History of significant losses and accumulated deficit, making historical operating performance an unreliable indicator for investment decisions.
• Indebtedness under the Callodine loan facility subjects the company to financial covenants and restrictions that could adversely affect liquidity and financial condition.
• No assurance that the digital health engagement platform will achieve broad adoption by healthcare providers, employers, health plans, or other enterprise customers.
• Dependence on third-party manufacturers and suppliers, creating vulnerability to supply shortages, problems, and price fluctuations.
• Reliance on Apple App Store and Google Play Store for application distribution, with risks from changes in terms or platform unavailability.
• Exposure to fluctuations in currency exchange rates due to international operations in Israel and India.
• Risks associated with international relationships, including geopolitical tensions and military instability in Israel, which could disrupt operations.
• Potential for undetected errors, defects, or bugs in the Dario platform and associated business processes, limiting service provision and diminishing attractiveness.
• Reliance on key members of the management team and the need to attract and retain highly skilled personnel.
• Outcomes-based contracts and reimbursement arrangements may not achieve expected results and could expose the company to financial and operational risks.
• The regulatory clearance process for medical devices is expensive, time-consuming, and uncertain, potentially delaying or preventing commercialization.
• Risks related to AI and machine learning technologies, including model accuracy, bias, privacy, intellectual property, cybersecurity, third-party dependencies, and evolving regulation.
• Failure to obtain or maintain patents, licensing agreements, and other intellectual property could materially impact the ability to compete effectively.
• Significant competition in the digital health and connected health device markets, potentially leading to pricing pressure and lower margins.
• Risk of Nasdaq delisting if the company fails to maintain compliance with listing criteria, particularly the minimum bid price requirement.
• Anti-takeover provisions in charter documents and Delaware law could discourage, delay, or prevent a change in control.

Future Outlook

The company expects to incur future net losses and its transition to profitability is dependent on successful commercialization, expanding its contracted member base, increasing utilization among existing customers, retaining and renewing contracts, and managing operating expenses. Management believes it has sufficient funds for at least the next twelve months, but will continue to depend on raising additional capital through debt or equity offerings, or cost-saving plans. The company plans to continue the phased rollout of DarioIQ in 2026, broaden its D2C offerings, explore additional condition areas, and initiate targeted deployments with select B2B customers, while refining AI capabilities and monitoring the impact of DarioSHIFT on operational costs and revenue ratios.

Management Comments

• Management believes that its D2C marketplace roots and continued focus delivers better user experiences, longer sustained engagement, stronger clinical outcomes, at the most affordable prices, that then delivers the highest return on investment (ROI) in the industry.
• Management believes that its future viability will continue to depend largely on its ability to attract and retain highly skilled managerial, sales, scientific and technical personnel.
• Management believes that its current operating budget includes various assumptions concerning the level and timing of cash receipts and cash outlays for operating expenses and capital expenditures and that it has sufficient funds to support its operation for at least a period of twelve months from the date of the issuance of these consolidated financial statements.

Industry Context

StockSavvy.ai notes that DarioHealth operates in a highly competitive and consolidating digital health market, where there is increasing demand for integrated 'whole-person' solutions and higher ROI from employers and health plans. The company's strategy to differentiate through its D2C origins, extensive clinical validation, AI-driven personalization, and bundled offerings aligns with these industry trends. Competitors like Teladoc Health and MDLive offer broad virtual care but struggle with profitability at scale, while more focused players like Omada Health and Virta Health often lack DarioHealth's multi-condition scope and reported ROI. DarioHealth's emphasis on proprietary hardware-generated data for its AI models provides a structural advantage over pure software platforms, positioning it to potentially capture market share in a landscape increasingly valuing data quality and demonstrable outcomes.

Comparison to Industry Standards

• DarioHealth claims to deliver the industry's highest ROI for customers, including employers, health plans, and pharmaceutical companies, generally exceeding 5:1, which is significantly higher than the 2:1 ROI that recent surveys indicate is no longer adequate for employers and health plans.
• The company reports achieving among the highest levels of A1c reduction (1.4 to 2.3 points) among leading digital health companies focused on diabetes, and 10% weight loss over 12 months, which it states is the industry's highest level for digital self-care.
• DarioHealth's behavioral health offering decreases symptoms of stress, anxiety, and depression by 25-30% in 8 weeks or less, with sustained engagement rates of close to 60% at 2 months, 40% at 12 months, and 30% at three years, which are strong engagement metrics in the digital mental health space.
• The company differentiates itself by offering a comprehensive whole-person digital health platform covering six different medical conditions, addressing 'point solution fatigue' expressed by employers and health plans, a trend that many competitors like Omada Health or specialized behavioral health providers like Lyra Health do not fully match.
• DarioHealth's AI is trained on 13 billion proprietary data points from its own connected hardware devices over more than a decade, a 'structural advantage' that pure software platforms, such as those from Teladoc Health or Headspace, cannot replicate through technology investment alone.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any pending legal proceeding, nor is its property the subject of a pending legal proceeding that is believed to be material to the financial condition of the business.

Related Party Transactions

• Adam Stern, a member of the Board of Directors, has an interest in Aegis Capital Corp., which served as a placement agent for the Series C Preferred Stock offering and received associated fees. Aegis also has financial advisory and sales fee agreements with the company.
• Lawrence Leisure, a member of the Board of Directors, is a member of NearWater Growth LCC, a consulting firm that has provided investment and business consulting services to the company since 2021. NearWater received shares of common stock, warrants, and a fixed monthly cash retainer.

Stakeholder Impact

• **Shareholders:** Experience dilution from ongoing equity raises and conversions of preferred stock. The strategic review could lead to a value-maximizing event or further uncertainty. Continued losses and Nasdaq delisting risk pose concerns.
• **Employees:** Benefit from equity incentive plans and potential for growth within a company focused on operational efficiency and strategic expansion. Management changes and post-merger integration activities may impact roles.
• **Customers (Employers, Health Plans, Pharma):** Benefit from an expanding 'whole-person' digital health platform, AI-driven personalization, and strong clinical outcomes. The company's focus on high ROI and bundled solutions aims to reduce 'point solution fatigue' and deliver value.
• **Patients/Users:** Gain access to a comprehensive digital health platform with FDA-cleared devices, AI-powered personalized care, and virtual coaching for chronic conditions and behavioral health, with demonstrated clinical efficacy.
• **Creditors (Callodine Lenders):** Have a secured credit facility, but the company's missed covenant and subsequent amendment highlight ongoing monitoring and potential risks related to repayment, despite deferred principal payments.

Next Steps

• Continue the phased rollout of DarioIQ, broadening availability within D2C offerings and exploring additional condition areas.
• Initiate targeted deployments of DarioIQ with select employer and health plan customers, subject to ongoing evaluation of safety, performance, and customer needs.
• Refine DarioIQ's capabilities, safeguards, and integration points across the platform.
• Continue to mature DarioSHIFT with meaningful usage and deployment of AI agents and tools, monitoring impact on operational costs and revenue ratios.
• The strategic review process will continue to consider a full range of potential opportunities including a sale, merger, strategic business combination, or continued execution of the current strategy.

Key Dates

Recommendation

DarioHealth exhibits a mixed financial picture with declining revenues but improved operational efficiency and reduced cash burn from operations. The significant net loss attributable to common shareholders and ongoing need for capital raises are concerning. However, strong customer growth, strategic investments in AI, and a comprehensive clinical evidence base provide a foundation for future potential. The ongoing strategic review could be a catalyst for value creation or further uncertainty. Given the current financial challenges balanced against strategic progress and potential for a transformative event, a 'hold' recommendation is appropriate for investors to monitor the outcome of the strategic review and the company's path to profitability.

Keywords

Digital Health, Chronic Care Management, AI Health Platform, Cardiometabolic Health, Behavioral Health, SEC 10-K, DarioHealth, Telehealth, Medical Devices, SaaS, Corporate Governance, Financial Performance, Strategic Review, Nasdaq